The field of Alzheimer’s research has experienced a period of rapid development, marking a departure from the limited options available just four or five years ago. According to Dr. Jason Karlawish, co-director of the Penn Memory Center, the current state of diagnosis and treatment represents a revolutionary change in how the disease is managed.

A primary driver of this shift is the emergence of new therapeutic options, specifically the drugs lecanemab and donanemab. Unlike previous treatments that primarily addressed symptoms, these new medications are designed to slow the biological progression of the disease. These drugs have recently become available for clinical use, signaling a new phase in Alzheimer's care. While the medical community views these developments as significant progress, the practical implementation of these treatments in broader healthcare settings remains an ongoing area of focus for researchers and clinicians alike.